Table 4 CIMP studies in HCC
From: DNA methylation: potential biomarker in Hepatocellular Carcinoma
Genes used to define CIMP | HCC patients (n) | Clinicopathological correlation | Validation method | Publication | Year |
|---|---|---|---|---|---|
ER, c-MYC, p14, p15, p16, p53, RB1, RASSF1A, WT1 | 50 | AFP level | MSP | Zhang et al. [96] | 2007 |
E2F1, p15, p16, p21, p27, p300, p53, RB, WT1 | 120 | Metastasis | MSP | Zhang et al. [97] | 2008 |
CDH1, p14, p15, p16, p21, RB1, RASSF1A, SYK, TIMP3, WT1 | 60 | Metastasis, tumor stage | MSP | Cheng et al. [98] | 2010 |
CDH1, DAPK, GSTP1, p16, SOCS1, SYK, XAF1 | 65 | AFP, RFS, tumor numbers | MSP | Wu et al. [100] | 2010 |
GSTP1, MGMT, OPCML, p14, p15, p16, p73, RARβ, SOCS1 | 115 | OS, RFS | MSP | Li et al. [99] | 2010 |
APC, CDH1, DKK, DLC1, RUNX3, SFRP1, WIF1 | 108 | AFP level, DFS, Gender, HBV status, tumor stage | MSP | Liu et al. [101] | 2011 |
APC, GSTP1, HIC1, p16, PRDM2, RASSF1A, RUNX3, SOCS1 | 177 | DFS | Methylight | Nishida et al. [102] | 2012 |